OBJECTIVE: Hematopoietic progenitor cells are able to induce neovascularization of ischemic myocardium, inhibit apoptosis, and prevent heart failure. They express functional CC chemokine-binding receptor 3 (CCR3) and CXC chemokine-binding receptor 4 (CXCR4); however, the role of those receptors in migration of progenitor cells into the ischemic myocardium is unknown. METHODS: Myocardial infarction was surgically induced in athymic nude rats, and human bone marrow-derived CD34+ cells or saline was injected into the tail vein. Cell chemotaxis was studied in vitro using chemotaxis chambers with or without concomitant stimulation with eotaxin or stromal cell-derived factor-1. Cell migration into ischemic myocardium was evaluated by immunohistochemistry. CCR3 and CXCR4 antibodies or local injections of stromal cell-derived factor-1 were used to investigate the role of chemokine expression in the migration capacity of the injected cells. Morphologic analysis included evaluation of apoptosis and capillary density in the ischemic myocardium. RESULTS: Ischemic rat myocardium demonstrated induced messenger RNA expression for the CCR3-binding chemokines eotaxin, RANTES (regulated on activation, normal T expressed and secreted), and monocyte chemotactic protein-3, but not the CXCR4-binding chemokine stromal cell-derived factor-1. Migration of human angioblasts to ischemic rat myocardium was inhibited by a blocking anti-CCR3 monoclonal antibody, but not by a blocking anti-CXCR4 monoclonal antibody, which instead inhibited migration to bone marrow. Finally, intramyocardial injection of stromal cell-derived factor-1 redirected migration of human angioblasts to ischemic rat hearts, resulting in augmented neovascularization, enhanced cardiomyocyte survival, and functional cardiac recovery. CONCLUSIONS: CCR3-dependent chemokine interactions regulate endogenous migration of CD34+ progenitors from bone marrow to ischemic but not to normal myocardium. Manipulating CXCR4-dependent interactions could enhance the efficacy of cell therapy after myocardial infarction.
OBJECTIVE: Hematopoietic progenitor cells are able to induce neovascularization of ischemic myocardium, inhibit apoptosis, and prevent heart failure. They express functional CC chemokine-binding receptor 3 (CCR3) and CXC chemokine-binding receptor 4 (CXCR4); however, the role of those receptors in migration of progenitor cells into the ischemic myocardium is unknown. METHODS:Myocardial infarction was surgically induced in athymic nude rats, and human bone marrow-derived CD34+ cells or saline was injected into the tail vein. Cell chemotaxis was studied in vitro using chemotaxis chambers with or without concomitant stimulation with eotaxin or stromal cell-derived factor-1. Cell migration into ischemic myocardium was evaluated by immunohistochemistry. CCR3 and CXCR4 antibodies or local injections of stromal cell-derived factor-1 were used to investigate the role of chemokine expression in the migration capacity of the injected cells. Morphologic analysis included evaluation of apoptosis and capillary density in the ischemic myocardium. RESULTS:Ischemicrat myocardium demonstrated induced messenger RNA expression for the CCR3-binding chemokines eotaxin, RANTES (regulated on activation, normal T expressed and secreted), and monocyte chemotactic protein-3, but not the CXCR4-binding chemokine stromal cell-derived factor-1. Migration of human angioblasts to ischemicrat myocardium was inhibited by a blocking anti-CCR3 monoclonal antibody, but not by a blocking anti-CXCR4 monoclonal antibody, which instead inhibited migration to bone marrow. Finally, intramyocardial injection of stromal cell-derived factor-1 redirected migration of human angioblasts to ischemicrat hearts, resulting in augmented neovascularization, enhanced cardiomyocyte survival, and functional cardiac recovery. CONCLUSIONS:CCR3-dependent chemokine interactions regulate endogenous migration of CD34+ progenitors from bone marrow to ischemic but not to normal myocardium. Manipulating CXCR4-dependent interactions could enhance the efficacy of cell therapy after myocardial infarction.
Authors: Patti C Zeidler-Erdely; Terence G Meighan; Aaron Erdely; Jeffrey S Fedan; Janet A Thompson; Suzan Bilgesu; Stacey Waugh; Stacey Anderson; Nikki B Marshall; Aliakbar Afshari; Walter McKinney; David G Frazer; James M Antonini Journal: Inhal Toxicol Date: 2014-08-20 Impact factor: 2.724
Authors: Lisandra E de Castro Brás; Courtney A Cates; Kristine Y DeLeon-Pennell; Yonggang Ma; Rugmani Padmanabhan Iyer; Ganesh V Halade; Andriy Yabluchanskiy; Gregg B Fields; Susan T Weintraub; Merry L Lindsey Journal: Antioxid Redox Signal Date: 2014-02-19 Impact factor: 8.401
Authors: Aditi Nayak; Colin Neill; Robert L Kormos; Luigi Lagazzi; Indrani Halder; Charles McTiernan; Jennifer Larsen; Ana Inashvili; Jeffrey Teuteberg; Timothy N Bachman; Karen Hanley-Yanez; Dennis M McNamara; Marc A Simon Journal: J Heart Lung Transplant Date: 2016-12-23 Impact factor: 10.247
Authors: William Hiesinger; John R Frederick; Pavan Atluri; Ryan C McCormick; Nicole Marotta; Jeffrey R Muenzer; Y Joseph Woo Journal: J Thorac Cardiovasc Surg Date: 2010-11 Impact factor: 5.209
Authors: Adelina Curaj; Mareike Staudt; Roxana Fatu; Andreas O Kraaijeveld; Joachim Jankowski; Erik A L Biessen; Elisa A Liehn Journal: Discoveries (Craiova) Date: 2015-06-30
Authors: Rakhee N Urankar; Robert M Lust; Erin Mann; Pranita Katwa; Xiaojia Wang; Ramakrishna Podila; Susana C Hilderbrand; Benjamin S Harrison; Pengyu Chen; Pu Chun Ke; Apparao M Rao; Jared M Brown; Christopher J Wingard Journal: Part Fibre Toxicol Date: 2012-10-16 Impact factor: 9.400